STAT3 contributes to cisplatin resistance, modulating EMT markers, and the mTOR signaling in lung adenocarcinoma

• Main Authors: Ana Paula Morelli, Tharcísio Citrângulo Tortelli, Jr, Mariana Camargo Silva Mancini, Isadora Carolina Betim Pavan, Luiz Guilherme Salvino Silva, Matheus Brandemarte Severino, Daniela Campos Granato, Nathalie Fortes Pestana, Luis Gustavo Saboia Ponte, Guilherme Francisco Peruca, Bianca Alves Pauletti, Daniel Francisco Guimarães dos Santos, Jr, Leandro Pereira de Moura, Rosângela Maria Neves Bezerra, Adriana Franco Paes Leme, Roger Chammas, Fernando Moreira Simabuco
• Format: Article
• Language: English
• Published: Elsevier 2021-10-01
• Series: Neoplasia: An International Journal for Oncology Research
• Subjects: Lung cancer; Cisplatin; Proteomics; STAT3; mTOR; Rapamycin
• Online Access: http://www.sciencedirect.com/science/article/pii/S1476558621000683

Lung cancer is the second leading cause of cancer death worldwide and is strongly associated with cisplatin resistance. The transcription factor signal transducer and activator of transcription 3 (STAT3) is constitutively activated in cancer cells and coordinates critical cellular processes as survival, self-renewal, and inflammation. In several types of cancer, STAT3 controls the development, immunogenicity, and malignant behavior of tumor cells while it dictates the responsiveness to radio- and chemotherapy. It is known that STAT3 phosphorylation at Ser727 by mechanistic target of rapamycin (mTOR) is necessary for its maximal activation, but the crosstalk between STAT3 and mTOR signaling in cisplatin resistance remains elusive. In this study, using a proteomic approach, we revealed important targets and signaling pathways altered in cisplatin-resistant A549 lung adenocarcinoma cells. STAT3 had increased expression in a resistance context, which can be associated with a poor prognosis. STAT3 knockout (SKO) resulted in a decreased mesenchymal phenotype in A549 cells, observed by clonogenic potential and by the expression of epithelial-mesenchymal transition markers. Importantly, SKO cells did not acquire the mTOR pathway overactivation induced by cisplatin resistance. Consistently, SKO cells were more responsive to mTOR inhibition by rapamycin and presented impairment of the feedback activation loop in Akt. Therefore, rapamycin was even more potent in inhibiting the clonogenic potential in SKO cells and sensitized to cisplatin treatment. Mechanistically, STAT3 partially coordinated the cisplatin resistance phenotype via the mTOR pathway in non-small cell lung cancer. Thus, our findings reveal important targets and highlight the significance of the crosstalk between STAT3 and mTOR signaling in cisplatin resistance. The synergic inhibition of STAT3 and mTOR potentially unveil a potential mechanism of synthetic lethality to be explored for human lung cancer treatment.